13 research outputs found
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis
Liver fibrosis, a common hallmark of chronic liver disease (CLD), is characterized by the accumulation of extracellular matrix secreted by activated hepatic fibroblasts and stellate cells (HSC). Fibrogenesis involves multiple cellular and molecular processes and is intimately linked to chronic hepatic inflammation. Importantly, it has been shown to promote the loss of liver function and liver carcinogenesis. No effective therapies for liver fibrosis are currently available. We examined the anti-fibrogenic potential of a new drug (CM414) that simultaneously inhibits histone deacetylases (HDACs), more precisely HDAC1, 2, and 3 (Class I) and HDAC6 (Class II) and stimulates the cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway activity through phosphodiesterase 5 (PDE5) inhibition, two mechanisms independently involved in liver fibrosis. To this end, we treated Mdr2-KO mice, a clinically relevant model of liver inflammation and fibrosis, with our dual HDAC/PDE5 inhibitor CM414. We observed a decrease in the expression of fibrogenic markers and collagen deposition, together with a marked reduction in inflammation. No signs of hepatic or systemic toxicity were recorded. Mechanistic studies in cultured human HSC and cholangiocytes (LX2 and H69 cell lines, respectively) demonstrated that CM414 inhibited pro-fibrogenic and inflammatory responses, including those triggered by transforming growth factor β (TGFβ). Our study supports the notion that simultaneous targeting of pro-inflammatory and fibrogenic mechanisms controlled by HDACs and PDE5 with a single molecule, such as CM414, can be a new disease-modifying strateg
Fatal familial insomnia: clinical, neuropathological, and genetic description of a Spanish family
The clinical presentation and evolution, neuropathological findings, and genotyping of three members of a Spanish family affected with fatal familial insomnia are reported. The mother and two of her offspring developed a rapidly evolving disease with insomnia and behavioural disorders as the initial symptoms and died between 5 and 10 months after the onset of the illness. Frontal brain biopsy in the mother disclosed only non-significant spongiosis, and full neuropathological examination of her offspring showed thalamic and olivary degeneration with isolated focal cortical spongiosis. Genetic examination could only be performed in the contemporary patients and both harboured the prion protein (PrP) 178Asn mutation and homozygous 129 Met/Met genotype.
Epigenetics in liver fibrosis: could HDACs be a therapeutic target?
Chronic liver diseases (CLD) represent a worldwide health problem. While CLDs may
have diverse etiologies, a common pathogenic denominator is the presence of liver fibrosis. Cirrhosis,
the end-stage of CLD, is characterized by extensive fibrosis and is markedly associated with the
development of hepatocellular carcinoma. The most important event in hepatic fibrogenesis is
the activation of hepatic stellate cells (HSC) following liver injury. Activated HSCs acquire a
myofibroblast-like phenotype becoming proliferative, fibrogenic, and contractile cells. While transient
activation of HSCs is part of the physiological mechanisms of tissue repair, protracted activation
of a wound healing reaction leads to organ fibrosis. The phenotypic changes of activated HSCs
involve epigenetic mechanisms mediated by non-coding RNAs (ncRNA) as well as by changes in
DNA methylation and histone modifications. During CLD these epigenetic mechanisms become
deregulated, with alterations in the expression and activity of epigenetic modulators. Here we
provide an overview of the epigenetic alterations involved in fibrogenic HSCs transdifferentiation
with particular focus on histones acetylation changes. We also discuss recent studies supporting the
promising therapeutic potential of histone deacetylase inhibitors in liver fibrosis
Epigenetics in liver fibrosis: could HDACs be a therapeutic target?
Chronic liver diseases (CLD) represent a worldwide health problem. While CLDs may
have diverse etiologies, a common pathogenic denominator is the presence of liver fibrosis. Cirrhosis,
the end-stage of CLD, is characterized by extensive fibrosis and is markedly associated with the
development of hepatocellular carcinoma. The most important event in hepatic fibrogenesis is
the activation of hepatic stellate cells (HSC) following liver injury. Activated HSCs acquire a
myofibroblast-like phenotype becoming proliferative, fibrogenic, and contractile cells. While transient
activation of HSCs is part of the physiological mechanisms of tissue repair, protracted activation
of a wound healing reaction leads to organ fibrosis. The phenotypic changes of activated HSCs
involve epigenetic mechanisms mediated by non-coding RNAs (ncRNA) as well as by changes in
DNA methylation and histone modifications. During CLD these epigenetic mechanisms become
deregulated, with alterations in the expression and activity of epigenetic modulators. Here we
provide an overview of the epigenetic alterations involved in fibrogenic HSCs transdifferentiation
with particular focus on histones acetylation changes. We also discuss recent studies supporting the
promising therapeutic potential of histone deacetylase inhibitors in liver fibrosis
Dual inhibition of DNA methyltransferase 1 and the histone methyltransferase G9a as a new therapeutic strategy in hepatoblastoma
Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial condition with a complex etiology. Its incidence is increasing globally in parallel with the obesity epidemic, and it is now considered the most common liver disease in Western countries. The precise mechanisms underlying the development and progression of NAFLD are complex and still poorly understood. The dysregulation of epigenetic and epitranscriptomic mechanisms is increasingly recognized to play pathogenic roles in multiple conditions, including chronic liver diseases. Here, we have performed a comprehensive analysis of the expression of epigenetic and epitranscriptomic genes in a total of 903 liver tissue samples corresponding to patients with normal liver, obese patients, and patients with non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), advancing stages in NAFLD progression. We integrated ten transcriptomic datasets in an unbiased manner, enabling their robust analysis and comparison. We describe the complete landscape of epigenetic and epitranscriptomic genes’ expression along the course of the disease. We identify signatures of genes significantly dysregulated in association with disease progression, particularly with liver fibrosis development. Most of these epigenetic and epitranscriptomic effectors have not been previously described in human NAFLD, and their altered expression may have pathogenic implications. We also performed a comprehensive analysis of the expression of enzymes involved in the metabolism of the substrates and cofactors of epigenetic and epitranscriptomic effectors. This study provides novel information on NAFLD pathogenesis and may also guide the identification of drug targets to treat this condition and its progression towards hepatocellular carcinoma
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis
Liver fibrosis, a common hallmark of chronic liver disease (CLD), is characterized by
the accumulation of extracellular matrix secreted by activated hepatic fibroblasts and stellate cells (HSC). Fibrogenesis involves multiple cellular and molecular processes and is intimately linked
to chronic hepatic inflammation. Importantly, it has been shown to promote the loss of liver
function and liver carcinogenesis. No effective therapies for liver fibrosis are currently available.
We examined the anti-fibrogenic potential of a new drug (CM414) that simultaneously inhibits
histone deacetylases (HDACs), more precisely HDAC1, 2, and 3 (Class I) and HDAC6 (Class II) and
stimulates the cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway activity
through phosphodiesterase 5 (PDE5) inhibition, two mechanisms independently involved in liver
fibrosis. To this end, we treated Mdr2-KO mice, a clinically relevant model of liver inflammation
and fibrosis, with our dual HDAC/PDE5 inhibitor CM414. We observed a decrease in the expression
of fibrogenic markers and collagen deposition, together with a marked reduction in inflammation.
No signs of hepatic or systemic toxicity were recorded. Mechanistic studies in cultured human
HSC and cholangiocytes (LX2 and H69 cell lines, respectively) demonstrated that CM414 inhibited
pro-fibrogenic and inflammatory responses, including those triggered by transforming growth factor
β (TGFβ). Our study supports the notion that simultaneous targeting of pro-inflammatory and
fibrogenic mechanisms controlled by HDACs and PDE5 with a single molecule, such as CM414,
can be a new disease-modifying strategy
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis
Liver fibrosis, a common hallmark of chronic liver disease (CLD), is characterized by
the accumulation of extracellular matrix secreted by activated hepatic fibroblasts and stellate cells (HSC). Fibrogenesis involves multiple cellular and molecular processes and is intimately linked
to chronic hepatic inflammation. Importantly, it has been shown to promote the loss of liver
function and liver carcinogenesis. No effective therapies for liver fibrosis are currently available.
We examined the anti-fibrogenic potential of a new drug (CM414) that simultaneously inhibits
histone deacetylases (HDACs), more precisely HDAC1, 2, and 3 (Class I) and HDAC6 (Class II) and
stimulates the cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) pathway activity
through phosphodiesterase 5 (PDE5) inhibition, two mechanisms independently involved in liver
fibrosis. To this end, we treated Mdr2-KO mice, a clinically relevant model of liver inflammation
and fibrosis, with our dual HDAC/PDE5 inhibitor CM414. We observed a decrease in the expression
of fibrogenic markers and collagen deposition, together with a marked reduction in inflammation.
No signs of hepatic or systemic toxicity were recorded. Mechanistic studies in cultured human
HSC and cholangiocytes (LX2 and H69 cell lines, respectively) demonstrated that CM414 inhibited
pro-fibrogenic and inflammatory responses, including those triggered by transforming growth factor
β (TGFβ). Our study supports the notion that simultaneous targeting of pro-inflammatory and
fibrogenic mechanisms controlled by HDACs and PDE5 with a single molecule, such as CM414,
can be a new disease-modifying strategy